[Olmesartan-associated Enteropathy]

Long Zou1, Qiang Wang1, Yue Li1

  • 1Department of Gastroenterology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.

Insights

Olmesartan, an antihypertensive drug, can cause severe gastrointestinal issues like chronic diarrhea and weight loss, known as olmesartan-associated enteropathy. Patients recover after stopping the medication, broadening differential diagnoses for malabsorption syndromes.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Internal Medicine

Background:

  • Olmesartan is a widely prescribed angiotensin II receptor blocker for hypertension.
  • Recent studies link olmesartan use to severe gastrointestinal adverse events.
  • These events include chronic diarrhea, intestinal malabsorption, and weight loss.

Purpose of the Study:

  • To review the potential pathogenesis of olmesartan-associated enteropathy (OAE).
  • To describe the clinical characteristics of OAE.
  • To enhance the differential diagnosis of chronic diarrhea and malabsorption.

Main Methods:

  • Review of case reports and cohort studies.
  • Analysis of clinical presentations and patient outcomes.
  • Discussion of proposed pathophysiological mechanisms.

Main Results:

  • Olmesartan administration is associated with a distinct enteropathy (OAE).
  • Symptoms include severe diarrhea, malabsorption, and weight loss.
  • Discontinuation of olmesartan leads to patient recovery.

Conclusions:

  • OAE is a significant adverse effect of olmesartan therapy.
  • Recognizing OAE is crucial for accurate diagnosis of unexplained GI symptoms.
  • This review expands the understanding of drug-induced enteropathies.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
1.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
553
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
261
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
868
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
401
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
65